Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies

Annals of Oncology

Volumn 25, Issue 11, 2014, Pages 2147-2155

  Moran, T ^a   Wei, J ^b   Cobo, M ^c   Qian, X ^b   Domine, M ^d   Zou, Z ^b   Bover, I ^e   Wang, L ^b   Provencio, M ^f   Yu, L ^b   Chaib, I ^a   You, C ^g   Massuti, B ^h   Song, Y ⁱ   Vergnenegre, A ^j   Lu, H ^k   Lopez Vivanco, G ^l   Hu, W ^b   Robinet, G ^m   Yan, J ^b   Insa, A ⁿ   Xu, X ^o   Majem, M ^p   Chen, X ^q   de las Penas R ^r   Karachaliou, N ^s   Sala, M A ^t   Wu, Q ^u   Isla, D ^v   Zhou, Y ^u   Baize, N ^w   Zhang, F ^x   Garde, J ^y   Germonpre, P ^z   Rauh, S ^aa   AlHusaini, H ^ab   Sanchez Ronco, M ^ac   Drozdowskyj, A ^ad   Sanchez, J J ^ae   Camps, C ^af   Liu, B ^b   Rosell, R ^a,ag,ah   more..

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^e HOSPITAL SON LLÀTZER   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g Suqian General Hospital   (China)

^h HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

ⁱ JINLING HOSPITAL   (China)

^j LIMOGES UNIVERSITY HOSPITAL   (France)

^k Taizhou General Hospital   (China)

^l HOSPITAL DE CRUCES   (Spain)

^m BREST UNIVERSITY HOSPITAL   (France)

ⁿ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^o NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

^p HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^q Huaian Third Hospital   (China)

^r HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

^s INSTITUT UNIVERSITARI DEXEUS   (Spain)

^t HOSPITAL DE BASURTO   (Spain)

^u Yixin General Hospital   (China)

^v HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^w ANGERS UNIVERSITY HOSPITAL   (France)

^x Maanshan General Hospital   (China)

^y HOSPITAL ARNAU DE VILANOVA   (Spain)

^z ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^aa Centre Hospitalier Emile Mayrisch   (Luxembourg)

^ab King Faisal Specialist Center and Research Center   (Saudi Arabia)

^ac UNIVERSITY OF ALCALÁ   (Spain)

^ad DMBS   (Spain)

^ae UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^af HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^ag Molecular Oncology Research (MORe) Foundation   (Spain)

^ah Cancer Therapeutics Innovation Group   (United States)

more..

Author keywords

Biomarkers; BRCA1; Clinical trial; Customized chemotherapy; Non small cell lung cancer; RAP80

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; CISPLATIN; DOCETAXEL; GEMCITABINE; MESSENGER RNA; RECEPTOR ASSOCIATED PROTEIN 80; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; DEOXYCYTIDINE; NUCLEAR PROTEIN; RAP80 PROTEIN, HUMAN; TAXOID;

ADULT; AGED; ARTICLE; CHINESE; EUROPEAN; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; CAUCASIAN; CHINA; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CHINA; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; TAXOIDS; TREATMENT OUTCOME;

EID: 84923199454     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu389     Document Type: Article

References (21)

1. Oliver TG, Mercer KL, Sayles LC et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 2010; 24: 837-852.
2. Cobo M, Isla D, Massuti B et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in nonsmall-cell lung cancer. J Clin Oncol 2007; 25: 2747-2754.
3. Bepler G, Williams C, Schell MJ et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2013; 31: 2404-2412.
4. Wang B, Matsuoka S, Ballif BA et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007; 316: 1194-1198.
5. Bunting SF, Callen E, Kozak ML et al. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol Cell 2012; 46: 125-135.
6. Quinn JE, James CR, Stewart GE et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007; 13: 7413-7420.
7. Quinn JE, Kennedy RD, Mullan PB et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63: 6221-6228.
8. Rottenberg S, Nygren AO, Pajic M et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 2007; 104: 12117-12122.
9. Boukovinas I, Papadaki C, Mendez P et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One 2008; 3: e3695.
10. Rosell R, Perez-Roca L, Sanchez JJ et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009; 4: e5133.
11. Yan J, Kim YS, Yang XP et al. Ubiquitin-interaction motifs of RAP80 are critical in its regulation of estrogen receptor alpha. Nucleic Acids Res 2007; 35: 1673-1686.
12. Bonanno L, Costa C, Majem M et al. The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Ann Oncol 2013; 24: 1130-1132.
13. Wang L, Wei J, Qian X et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008; 8: 97.
14. Wei J, Costa C, Ding Y et al. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst 2011; 103: 1552-1556.
15. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
16. Georgoulias V, Ardavanis A, Agelidou A et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 2004; 22: 2602-2609.
17. Bunting SF, Callen E, Wong N et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010; 141: 243-254.
18. Bonanno L, Costa C, Majem M et al. The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. Oncotarget 2013; 4: 1572-1581.
19. Nakada S, Yonamine RM, Matsuo K. RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1. Cancer Res 2012; 72: 4974-4983.
20. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481: 287-294.
21. Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013; 382: 720-731.